The Medical Challenge: Prolonged Labor

Dilafor addresses a critical unmet need in modern obstetrics: slow progress of labor.

• The Problem: Approximately 30?50% of term pregnancies require a planned start of labor (induction). However, current induction methods (such as mechanical balloons or hormonal prostaglandins) can be lengthy, painful, and unpredictable. Furthermore, even when labor starts, it often progresses too slowly, leading to "labor arrest."
• The Consequence: Prolonged labor is a primary driver of emergency Caesarean sections, instrumental deliveries (using vacuum or forceps), and post-partum hemorrhage. For the fetus, it increases the risk of oxygen deprivation (asphyxia) and infection.

Dilafor?s research identified that women who experience prolonged labor often suffer from a deficiency in heparan sulfate, a naturally occurring polysaccharide in the body that helps soften the cervix and synchronize uterine contractions.

Core Product: Tafoxiparin

Dilafor?s flagship proprietary candidate is Tafoxiparin.

Mechanism of Action

Tafoxiparin is a heparan sulfate mimetic. It is a chemically modified derivative of heparin (a common anticoagulant) that has been engineered to have low anticoagulant activity while retaining the biological properties relevant to labor.

• Cervical Ripening: Tafoxiparin works by remodeling the Extra Cellular Matrix (ECM) of the cervix. It effectively "supplements" the natural heparan sulfate levels in the tissue, causing the cervix to soften (ripen) and dilate.
• Myometrial Preparation: Unlike standard induction drugs that force contractions (often causing hyper-stimulation and fetal distress), Tafoxiparin prepares the uterus muscle (myometrium) to contract naturally and efficiently once labor begins.

Indication: Priming of Labor

The primary clinical application for Tafoxiparin is "Priming of Labor."

• Target Patient: Term pregnant women with an "unripe" cervix (low Bishop Score) who are scheduled for labor induction.
• Administration: The drug is designed for subcutaneous injection (similar to insulin or blood thinners), potentially allowing for self-administration by the patient at home in the days leading up to the scheduled delivery.
• Goal: To ripen the cervix so that labor starts spontaneously or requires minimal assistance, thereby reducing the "time to delivery" and lowering the rate of emergency C-sections.

Clinical Development and Research

Dilafor has conducted extensive clinical trials to validate the safety and efficacy of Tafoxiparin.

• Phase 2b Success (Priming of Labor): In June 2021, Dilafor reported positive results from a Phase 2b clinical trial involving first-time mothers. The study demonstrated that Tafoxiparin significantly improved cervical ripening compared to placebo. A significant proportion of women treated with Tafoxiparin entered spontaneous labor or achieved a ripe cervix without the need for traditional mechanical induction.
• Safety Profile: Across multiple studies involving hundreds of women, Tafoxiparin has shown a favorable safety profile for both mother and child, with no evidence of the hyper-contractility (over-frequent contractions) often associated with oxytocin or prostaglandin use.
• Historical Research (Labor Arrest): Previously, Dilafor investigated Tafoxiparin for the treatment of active labor arrest (halting slow labor after it has begun). While a Phase 2b study in 2018 proved the drug was safe, it did not meet its primary efficacy endpoint for this specific acute indication. Consequently, the company pivoted its primary focus to the preventative "priming" indication, which has shown superior clinical promise.

Corporate Background and Partners

Dilafor is a portfolio company of Karolinska Development AB, a Nordic investment firm that commercializes Nordic life science innovations.

• Manufacturing Partner: The company has a strategic partnership and ownership tie with Opocrin S.p.A., a leading Italian manufacturer of active pharmaceutical ingredients (APIs) derived from biological sources. This partnership secures the complex manufacturing supply chain required for heparin-derivative drugs.
• Intellectual Property: Dilafor holds a robust patent portfolio, including a key U.S. patent granted in 2023 that protects the use of Tafoxiparin for priming of labor through at least 2043.

Summary of Offerings

| Product / Service | Description | | :--- | :--- | | Tafoxiparin | A novel drug candidate (heparan sulfate mimetic) designed to treat prolonged labor. | | Priming Therapy | A therapeutic regimen intended to ripen the cervix and prepare the uterus for childbirth, potentially administered at home before hospital admission. | | Obstetric Research | Deep expertise in the biochemistry of the uterine cervix and the physiological processes of parturition. |